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Abstract
Classically, the actions of progesterone (P4) are attributed to the binding of nuclear progesterone receptor (PR) and
subsequent activation of its downstream target genes. These mechanisms, however, are not applicable to PR– or basal
phenotype breast cancer (BPBC) due to lack of PR in these cancers. Recently, the function of membrane progesterone
receptor alpha (mPRa) in human BPBC cell lines was studied in our lab. We proposed that the signaling cascades of
P4RmPRa pathway may play an essential role in controlling cell proliferation and epithelial mesenchymal transition (EMT)
of breast cancer. Using human breast cancer tissue microarrays, we found in this study that the average intensity of mPRa
expression, but not percentage of breast cancer with high level of mPRa expression (mPRa-HiEx), was significantly lower in
the TNM stage 4 patients compared to those with TNM 1–3 patients; and both average intensities of mPRa expression and
mPRa-HiEx rates were significantly higher in cancers negative for ER, as compared with those cancers with ER+. However,
after adjusting for age at diagnosis and/or TNM stage, only average intensities of mPRa expression were associated with ER
status. In addition, we found that the rates of mPRa-HiEx were significantly higher in cancers with epithelial growth factor
receptor–1 (EGFR+) and high level of Ki67 expression, indicating positive correlation between mPRa over expression and
EGFR or Ki67. Further analysis indicated that both mPRa-HiEx rate and average intensity of mPRa expression were
significantly higher in HER2+ subtype cancers (i.e. HER2+ER–PR–) as compared to ER+ subtype cancers. These data support
our hypothesis that P4 modulates the activities of the PI3K and cell proliferation pathways through the caveolar membrane
bound growth factor receptors such as mPRa and growth factor receptors. Future large longitudinal studies with larger
sample size and survival outcomes are necessary to confirm our findings.
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Introduction
Progesterone (P4) plays a central role in the reproductive
functions of both sexes. In females, P4 plays a critical role in
pregnancy and lactation because it induces a series of fundamental
events, such as ovulation, implantation, decidualization, parturi-
tion and breast development [1]. In males, P4 controls
spermatogenesis, acrosome reaction, and testosterone biosynthesis
[2,3]. Roles for P4 in non-reproductive tissues have also been
demonstrated in multiple physiological processes such as fat
metabolism, bone remodeling, immune responses, gastrointestinal
and renal functions [4,5,6,7,8]. The roles of female sex hormones
such as progesterone (P4) in the pathogenesis of breast cancer
remain unclear and the function of P4 in progesterone receptor
negative (PR–) or basal phenotype breast cancer (BPBC) is even
less well understood. Classically, the actions of P4 on cancer cells
are attributed to the binding of nuclear PR, translocation of P4/
PR complex into the nucleus, and subsequent activation of target
genes over the course of several hours. These mechanisms,
however, are not applicable to PR– or BPBC due to lack or very
low level of PR expression in these cancers. Recently, cell
membrane hormonal receptors, such as the mPR family, were
identified and demonstrated to be functional in human breast
cancer [9,10]. It is believed that the rapid responses of P4 are
initiated at the cell surface by binding to the membrane receptors
[11,12,13]. For examples, progestin, a synthetic P4, has been
shown to activate a variety of signaling pathways through mPRa
[9]. The binding of progestin to mPRa alters the secondary
messenger pathways through activation of the pertussis toxin-
sensitive inhibitory G-proteins and then activates the MAPK/Erk
1/2 pathway [9,10,14,15]. However, this theory has been debated
since others failed to demonstrate mPR on the cell surface or
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pling to G proteins [16].
Epithelial-mesenchymal transition (EMT), a key developmen-
tal process, is often activated during cancer invasion and
metastasis [17–18]. We previously co-localized mPRa, Cav-1,
and EGFR at a specified membrane structure, the caveolar
vesicle, and demonstrated that P4 reverses the mesenchymal
phenotypes of human BPBC cells via a caveolae bound
signaling complex namely mPRa, Cav-1, EGFR, and PI3K/
Akt [19]. Also, we found that nearly 90% of breast cancer
tissues stained positive for anti-mPRa antibody and the positive
rates for triple negative breast cancer (TNBC) and non TNBC
showed no significant difference [19]. However, our previous
study did not investigate the association between mPRa
expression with clinical characteristics, such as TNM stage,
tumor grade, and node status [19]. In addition, the previous
definition of mPRa positivity was based on the absolute
positivity of cancer, which led to a very high positive rate.
Assumingly it may mask the real association between mPRa
expression and other clinical characteristics. So far, no study has
examined the associations between mPRa expression with
survival or target therapy regimen selection biomarkers, such
as ER, PR, HER2, EGFR, AR, and Ki67. Thus, further
human studies are warranted on this unique molecular pathway
which may afford great potential to discover novel molecular
targets for treatment of PR negative or basal phenotype breast
cancer. In the current study, we assay tissue microarray slides of
breast cancer (mostly invasive ductal carcinomas with a few
invasive papillary or invasive tubular carcinomas) using a semi-
quantitative scoring system and investigate the association of
mPRa expression with the aforementioned breast cancer clinical
characteristics and target therapy relevant biomarkers. Our data
indicated that expression of mPRa was reversely correlated to
expression of ER and EGFR. MPRa may emerge as a potential
biomarker for breast cancer.
Methods and Materials
Tissue Microarray Slides and Clinicopathological
Characteristics
Two tissue microarrays consisting of 140 and 70 human breast
cancer cores and 10 and 24 adjacent benign breast tissue cores
respectively were purchased from Biomax US (Rockville, MD).
These tissue microarrays were constructed with different sets of
breast tissues with two 1.0 mm-cores from each breast tissue block.
Combined, there were 105 breast cancers and 17 adjacent benign
breast tissues in these two tissue microarrays. The tissue samples
have been successfully used in our previous study [19]. The
Biomax has provided detailed information (Table 1) on clinico-
pathological characteristics including age at breast cancer
diagnosis (age), clinical TNM stage (TNM), breast cancer
pathological grade (grade), lymph node involvement (node), as
well immunohistochemical stain results on the original tissue slides
including expression of estrogen receptor alpha (ERa), progester-
one receptor (PR), human epidermal growth factor receptor 2
(HER2), androgen receptor (AR), epithelial growth factor receptor
1 (EGFR), Ki67, and P53. The intensities or scores of some
immunostains (i.e. HER2 and EGFR) were provided as ‘‘–, +, ++,
+++’’ (or 0, 1, 2, 3) [20], in which some of the cancer cores were
scored as a range between two defined numbers, such as ‘‘+ _ ++
or ++ _ +++’’. In these cases, the mean numbers were taken as
their scores. Currently immunohistochemical stain for EGFR has
not been a routine test in breast cancer and therefore we define
EGFR positivity solely depending upon the intensity. If the score
of EGFR was $1, the breast cancer was considered as EGFR
positive. In the rest of immunostains (i.e. ER, PR, AR, Ki67, and
P53), both intensities (or scores) and proportions of the positive
areas (percentages as compared to total sample area) were
provided. In these cases, the immunostain scores were defined
based on both intensity and positive area (score=intensity 6
percentage of positive area) [21,22,23,24]. If the mean score of the
duplicate cancer cores was ,0.1, the breast cancer was considered
as negative (1_weak stain intensity and ,10% positive area).
Immunohistochemical Analysis (IHC)
In brief, after deparaffinization, rehydration, antigen retrieval,
and endogenous peroxidase blocking, the tissue microarray
Table 1. Clinicopathologic characteristics and
immunohistochemical features of breast cancer patients.
Characteristic Number of Cases Percent (%)
Age (y) #50 68 64.8
.50 37 35.2
TNM 0-T1 5 4.8
T2 55 52.4
T3 30 28.6
T4 15 14.3
Node 07 5 7 1 . 4
11 4 1 3 . 3
21 2 1 1 . 4
3 4 3.8
Grade 1- 16 15.5
2- 71 68.9
31 6 1 5 . 5
ER 0- 46 43.8
0.1- 20 19.1
1- 39 37.1
PR 0- 65 61.9
0.1- 22 21.0
1- 18 17.1
HER2 0- 42 40
1- 24 22.9
2- 39 38.1
AR 0-
0.1-
75
25
71.4
23.8
1- 5 4.8
EGFR 0- 57 81.4
1- 5 7.1
2- 8 11.4
Ki67 0- 15 21.5
0.1- 47 67.1
1- 8 11.4
P53 0- 51 72.9
0.1- 14 20
1- 5 7.1
mPRa ,1.5 59 56.19
$1.5 46 43.81
doi:10.1371/journal.pone.0035198.t001
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and then incubated with anti- mPRa antibody (1:200 dilution,
Santa Cruz, CA) at 4uC overnight, and subsequently incubated
with a secondary antibody at room temperature (see manual of
the ImmPRESS REAGENT kit, VECTOR Lab, CA). The
color was developed with the ImmPACT DAB kit (VECTOR
Lab, CA). Between the incubations, the slides were washed
twice with 16PBS buffer (5 min each) [25,26]. The specificity of
anti-mPRa antibody was demonstrated previously by Western
blotting cellular proteins isolated from known mPRa positive
(i.e. mPRa cDNA transfected MDA-MB231 cells) and mPRa
negative cells (MDA-MB231 cells)(Figure 1F). To further
exclude any non-specific stains from staining procedures,
following negative controls were included – (1) control slides
were stained without the primary antibody; (2) control slides
were incubated with a specific blocking peptide (cat# sc-
50111p, Santa Cruz, CA) prior to the primary antibody
incubations. The immunostained slides were counterstained
with Harris hematoxylin and evaluated using a Nikon
microscope (MICROPHOT-SA, Nikon, Japan) and an Olympus
digital camera (DP-71, Olympus, Japan).
Microscopic Scoring on mPRa
The mPRa immunostaining was evaluated using a semi-
quantitative scoring system [21,22,23,24] by one senior research
pathologist. The intensity of the immunostaining was defined
into three categories: 0=Negative; 1=a) Weak or mild positive
in most of the core or b) moderate positive for some area of the
core; 2=Moderate or strong positive for most area of the core
or above (Figure 1B – 1E). The scoring was done twice by the
same research pathologist separately using the same scoring
standards and blinded to the patients’ clinical data and the
immunohistochemical staining scores for various biomarkers
provided by the company. The final score for each case was
achieved by averaging the mPRa scores for two individual cores
of each case. Based on the intensity of mPRa, we considered
breast cancers with average score $1.5 (at least one core scored
1 and the other scored 2 or both scored $2) as ‘‘mPRa highly
expressed or mPRa -HiEx’’ in this study.
Statistical Analysis
The semi-quantitative mPRa expression score was expressed
as mean score 6 standard error (se) and the mPRa positive
(score $1.5) was expressed as frequency and percentage. We
compared the semi-quantitative score between subgroups of
each tumor characteristic using Kruskal-Wallis (K-W) test.
Generalized linear models were used to control the known
confounding factors of breast cancer as follows: age (continu-
ous), TNM stage (0–2, 3, 4). Pearson Chi-square and Fisher’s
exact tests were used when comparing the strong mPRa
expression distribution in different groups of human breast
cancers. Unconditional logistic regression models were used to
estimate the association between mPR positive and other tumor
characteristics additionally adjusting for age and TNM stage.
The proportions with strong mPRa expression in HER2+, triple
negative, and ER+ cancers were derived from Chi-Square test
and semi-quantitative score among these three groups derived
from Kruskal-Wallis test. All analyses were performed using SAS
9.2 software (SAS Institute, Cary, NC). The reported P values
were two-sided with statistical significance evaluated at 0.05.
Figure 1. Immunohistochemical stain intensities of mPRa and controls. Figure 1A shows the western blot assay of cellular proteins
(duplicates) isolated from MB231 and MB231-mPR (mPRa cDNA stably transfected MB231 cells). Figure 1B – 1E show the tissue microarray cores that
are negative (1B), weak (1C), moderate (1D), and strong positive (1E). The positive stain signals are indicated as black arrows. Figure 1F shows a
benign breast disease core with weak mPR positive stain in epithelium (black arrow) and strong positive stain in myoepithelium (brown arrow). Image
was taken a 206lens.
doi:10.1371/journal.pone.0035198.g001
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Relationship between mPRa and Clinicopathological
Characteristics of the Patients
As shown in Table 2, the mPRa- HiEx rate tended to decrease
with increasing TNM stage, although this result was not
statistically significantly different (TNM stage 0-III vs. TNM stage
IV, P=0.17). However, when the average scores of mPRa
expression were evaluated, the difference became statistically
significant (P=0.02). There were no significant differences for
other clinical and pathological factors such as age at diagnosis,
tumor grade, and node status.
Levels of mPRa Expression and Status of ER, PR, AR, and
HER2
The percentage of cancers with mPRa-HiEx did not signifi-
cantly differ by ER status (54.35% vs. 35.59%, P=0.05).
However, average intensity of mPRa expression was higher in
ER negative vs. ER positive cancers (1.3560.08 vs. 1.0860.07,
P=0.02). After adjusting for age and/or TNM stage, the
association of mPRa intensities with ER remained (P=0.03).
Breast cancers with HER2 positive expression had a slightly higher
mPRa-HiEx rate compared to that in HER2 negative cancers
(54.05% vs. 38.24%, P=0.12, Table 2); in addition, the HER2
positive cancers were also associated with a significant elevated
level of mPRa expression, as compared to that in HER2 negative
cancers (1.3460.10 vs. 1.1360.07, P=0.07). None of these
differences, however, reached statistically significant level. The
expression of mPRa expression was not correlated with status of
PR and AR expressions.
Association of mPRa Expression with Expression of EGFR,
Ki67, and P53
The association of mPRa expression with cell proliferation
relevant biomarkers - EGFR, Ki67, and P53, were investigated.
The rate of mPRa-HiEx was significantly higher in cancers with
EGFR expression (61.54% vs. 24.56%, P=0.02); and after
adjusting for age and/or TNM stage, the association remained
(P=0.04, Table 2). However, when the average level of mPRa
expression was evaluated, EGFR expression was marginally
positively associated with mPRa (1.3160.17 vs. 1.0260.07,
P=0.04, Table 2). After adjusting for age and/or TNM stage,
this association became even weaker (P=0.08, Table 2). The
association of mPRa expression with Ki67 was interesting. There
was no significant difference found both average levels of mPRa
expression and mPRa-HiEx rate when we compared Ki67+can-
cers with Ki67– cancers. However, when we compared breast
cancers with higher Ki67 expression (score $0.3) with cancers
with lower or negative Ki67 expression (score ,0.3), the levels of
mPRa expression and mPRa-HiEx rate were both significantly
higher in former cancers (1.3060.1 vs. 0.9760.08, P=0.01,
59.09% vs. 18.75%, P=0.0007). These differences remained after
Table 2. Association of mPRa expression with various clinicopathological characteristics and pathway biomarkers.
Tumor Characteristic N mPRa Expression Score mPRa-High Expressed (score$1.5)
Mean ± se P value P value
b N’ N’/N (%) P value P value
b
TNM 0–2 60 1.2560.06 0.02
c 29 48.33 0.17
a,c
0.16
a,d
3 30 1.2660.10 13 43.33
4 15 0.8360.16 4 26.67
Node 0 75 1.2160.06 0.80 33 44.00 0.95
1–3 30 1.1760.12 13 43.33
Grade
e 1
2
16
71
1.4160.11
1.1360.07
0.16 10
27
62.50
38.03
0.18
3 16 1.2860.16 8 50.00
ER status – 46 1.3560.08 0.02 0.03 25 54.35 0.05 0.07
+ 59 1.0860.07 21 35.59
PR status – 65 1.2660.07 0.18 0.32 32 49.23 0.15 0.24
+ 40 1.1060.09 14 35.00
HER2 status – 68 1.1360.07 0.07 0.14 26 38.24 0.12 0.21
+ 37 1.3460.10 20 54.05
Ki67 – 15 0.9760.12 0.33 0.39 3 20.00 0.36
a 0.37
+ 55 1.1060.07 19 34.55
Ki67 ,0.3
$0.3
48
22
0.9760.08
1.3060.10
0.01 0.04 9
13
18.75
59.09
0.0007 0.01
EGFR
f – 57 1.0260.07 0.04 0.08 14 24.56 0.02
a 0.04
+ 13 1.3160.17 8 61.54
Kruskal-Wallis test, Chi-square test were used;
aP values calculated using Fisher’s exact test;
bAdditional adjusting for age, TNM stage;
cTNM stage 0–3 vs. TNM stage 4;
dTNM stage 0–2 vs. TNM stage 4;
eThere were two cases without grade information provided; f There were thirty five cases without the related information provided;
doi:10.1371/journal.pone.0035198.t002
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difference by level of P53 expression (data did not show).
MPRa Expression in Various Molecular Subtypes of Breast
Cancers
We evaluated whether mPRa expression was associated with
the molecular subtypes of breast cancers reported by Perou et al
[27,28]. As shown in Table 3, compared to ‘‘HER2+ subtype
cancers’’ (HER2+, ER–, PR–), mPRa-HiEx rate and average
levels of mPRa expression (59.26%, 1.4160.11) were reduced
among those with triple negative breast cancers (50%, 1.2860.12),
and further reduced among those with ‘‘ER+ subtype cancers’’
(35.00%, 1.0860.07). The mPRa-HiEx rate and average intensity
of mPRa expression were marginally or significantly higher in
HER2+ subtype cancers (i.e. HER2+ER-PR-) as compared to
ER+ subtype cancers (P=0.05, P=0.02, respectively). There were
no significant differences between TNBC and HER2+ subtype or
between TNBC and ER+ subtype cancers.
Discussion
Utilizing PCR assay, Dressing et al reported expression of
mPRa mRNA in both normal and malignant breast tissues [10].
Using an in vitro hormone binding technique and a FITC
conjugated BSA-progesterone, Pelekanou et al detected the
‘‘membrane-associated receptor for progesterone’’ in 57 of 61
breast cancers (94%) [29]. In our previous report, the protein
expression of mPRa was detected in 94 of 105 breast cancer
tissues, which was quite consistent with Pelekanou’s result [29]. In
our previous study, however, the association of expression levels of
mPRa with clinical and pathological characteristics, such as tumor
grade, node status, and TNM stage were not investigated. In
addition, the high positive rate defined by absolute positivity may
not be appropriated to evaluate the relationship of mPRa
expression and clinicalpathological characteristics. Assumingly it
may prevent the analysis of the association between mPRa
expression and clinicalpathological characteristics. In this study,
we used a semiquantitative scoring system and defined the cancers
as ‘‘over expressed’’ when they were stained with ‘increased level
of mPRa expression’ by referring to the positivity of normal breast
epithelium. We showed that the patients in earlier TNM stages (0–
3) remained constant high levels of mPRa expression (or higher
mPRa-HiEx rates). However, both mPRa expression level and
mPRa-HiEx rate were significantly lower or moderately lower
(48.33% vs. 26.67%, P=0.17) in patients with TNM 4 stage.
According to our best knowledge, our study provides the first line
of indication that expression of mPRa may be associated with
breast cancer TNM stage. Further study on breast cancer
prognosis and mPRa expression would be meaningful in clinic.
The role of progesterone (P4) signaling in breast cancer
development has attracted substantial interest, but there also
remains controversy [30]. It is believed that the physiological
actions of P4 is mediated through nuclear PR [30]. However, it
has been observed for many years that part of the physiological
actions of P4 cannot be explained by its genomic activity through
nuclear PR [30]. Substantial evidence indicates that non-genomic
steroid signaling, including P4 signaling, is mediated through
membrane- or cytoplasmic-localized classic steroid receptors, such
as mPRa [30]. So far, research has been very limited on the
physiological activity of mPRa and virtually no study has
investigated its activity in breast cancer pathogenesis. Depending
upon the experimental cell model system, cell context, and
duration of treatment, P4 can elicit either proliferative or
antiproliferative effects on breast cancer cells in vitro [31]. For
example, P4 induces cell growth and migration of T47D [32](an
ER+,P R +, and HER2+ cell line), but inhibits the cell proliferation
of MDA-MB468 cells, a human BPBC or TNBC cell line with
strong mPRa protein expression [19]. It seems that the status of
breast cancer triple markers, ER, PR, and HER2, plays an
essential role in determining the cell biological behavior of breast
cancer in responding to P4 treatment. In this study, we
demonstrated a negative correlation between mPRa and ER;
and the significance of the relationship between mPRa and ER
remained after adjusting for age at diagnosis and/or TNM stage,
indicating strong correlations existed in these receptors, even
though the percentages of cancers with mPRa-HiEx marginally
differ by ER status. To confirm these findings, further study with
larger sample sizes is essential.
Due to high throughput techniques, many novel biomarkers
with prognostic and predictive values were reported in recent
years, but very few of them have been validated and adopted for
clinical use [33]. According to ‘‘the American Society of Clinical
Oncology 2007 update of Recommendations for the Use of
Tumor Markers in Breast Cancer’’, only three biomarkers,
including ERa, PR and HER2 expression and/or amplification,
are recommended for routine clinical use for every patient with
primary invasive breast cancer [33,34]. Based upon the gene
expression profiles, Perou et al classified breast cancer into four
broad distinct groups: luminal A and B (ER+ subtype), HER2-
positive (HER2+ subtype), normal-breast-like and basal phenotype
breast cancer (BPBC) [27,28]. This classification, however, very
closely corresponds to the classifications identified based on ER/
PR/HER2 status [35]. The luminal cancers are almost all ER+
subtype; the HER2+subtype cancers are ER–/PR–, but have
amplification and over-expression of the HER2 gene; BPBC
cancers overlap mostly with triple negative (ER–/PR–/HER2–, or
TNBC) cancers [35]. Currently there is no current agreement on
the IHC criteria to classify cancers into various subtypes. In this
study, we classified the cancers based on their molecular subtypes
Table 3. Correlation between mPRa expression and molecular subtypes of breast cancer.
Subtype Total mPRa-High Expressed (score$1.5) mPRa Expression Score
n Percent (%) P value
a Mean ± se P value
b
HER2+ER–PR– 27 16 59.26 0.05 1.4160.11 0.02
HER2-ER–PR– 18 9 50.00 1.2860.12
ER+ 60 21 35.00 1.0860.07
ap-value from Chi-square test for ER+ vs. HER2+ER–PR–.
bp-value from Kruskal-Wallis test for ER+ vs. HER2+ER–PR–.
doi:10.1371/journal.pone.0035198.t003
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breast cancer development. As shown in Table 3, the ‘HER2+’
subtype cancers revealed the highest level of mPRa expression
while ‘ER+’ subtype cancers had the lowest level of mPRa
expression. These results seem to further support the potential
negative correlation between mPRa and ER. Moreover, in this
current study we confirmed our previous finding that the status of
mPRa expression in TNBC showed no difference as compared to
other cancer subtypes [19].
EGFR is one of the prominent hallmarks of triple negative
breast cancer (TNBC) and/or BPBC and over-expression of
EGFR has been used as a main therapeutic target for treatment of
TNBC [36,37,38]. It was assumed that P4 directly inactivates the
PI3K-snail-EMT pathway or interacts with caveolin-1 (Cav-1) and
modulates the activities of the EGFR and PI3K pathways, and
eventually suppresses cell proliferation and EMT. Caveolae are
special membrane structures of the cells concentrating a wide
variety of growth factor receptors including HER2 and EGFR
[39,40]. Cav-1 is a specific marker protein for caveolae and
expression of Cav-1 was associated with the most aggressive ‘basal-
like-phenotype’ breast cancer previously [41,42]. In this study, we
found that breast cancers with increased mPRa expression were
associated with higher EGFR HiEx rates, a positive correlation
that persisted even after adjusting the age at diagnosis and/or
TNM stage. This finding may support our previous theory that
mPRa signal pathway may cross react with growth factor receptor
(i.e. EGFR, HER2) pathways in responding to P4 stimulation.
Moreover, our data also revealed a potential positive correlation
between mPRa and strong Ki67 expression (score$0.3) which
further suggested the association of mPRa and cell proliferation,
even though this novel finding needs to be confirmed by large-
scale clinical studies.
As with all prevalent studies, one major concern is that the
temporal sequence is not clear. However, the biomarkers, such as
ER, Her-2, Ki67, and EGFR are in the relevant pathways and the
findings were consistent with that found in our in vitro studies.
Another concern is the small sample size, which may lead to type I
error. Thus, future large longitudinal studies with survival
outcomes and a larger sample size are necessary to confirm our
findings. The third concern is the representativeness of tissue
microarray. Although TMAs are constructed with duplicate cores
and we stained the slides in parallel settings, duplicate cores may
still not represent the entire tumors [43]. Thus, misclassification
could arise. This misclassification is likely to be non-differential by
clinical outcomes and non-differential misclassification may bias
the results to the null. This may generate bias in future studies if
different scoring systems are employed. Therefore, further study is
certainly needed to validate our findings and uncover the true
associations between mPRa and other biomakers.
In summary, our current data indicated that expression of
mPRa may have a negative correlation with ER expression.
Coordinately, mPRa expression was significantly higher in
HER2+ subtype cancers (i.e. HER2+ER–PR–) as compared to
ER+ subtype cancers. In addition, mPRa expression may also
associate with EGFR + cancers and cancers with higher level of
Ki67 expression. These data support our hypothesis that P4
interacts with caveolin-1 (Cav-1) and modulates the activities of
the PI3K pathways and cell proliferation through caveolar
membrane bound growth factor receptors, which may include
mPRa and HER2/EGFR [39,40]. MPRa may emerge as a novel
biomarker for breast cancer beyond the widely used ER, PR, and
HER2.
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